Positive data from AbbVie's HCV clinical development program presented at The Liver Meeting of AASLD

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high rates of sustained virologic response at 12 weeks post-treatment (SVR12) in non-cirrhotic patients with chronic hepatitis C virus (HCV) infection. After 12 weeks of treatment, SVR12 rates achieved were 97-100 percent in genotype 1 (GT1), 96-100 percent in genotype 2 (GT2) and 83-94 percent in genotype 3 (GT3) patients. These data are being presented at The Liver Meeting® 2015, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Separately, in a late-breaking presentation of the SURVEYOR-I study, data show non-cirrhotic GT1 chronic HCV patients who received a shorter duration of treatment for 8 weeks with ABT-493 and ABT-530 achieved a SVR12 rate of 97 percent.

"These results are encouraging and contribute to scientific knowledge about the potential for pan-genotypic options for treating chronic hepatitis C," said Fred Poordad, M.D., vice president of Academic and Clinical Affairs at The Texas Liver Institute in San Antonio. "These data mark another important step in the continued research to help address the unmet needs of patients and the medical community."

SURVEYOR-I and SURVEYOR-II are ongoing Phase 2 clinical studies that evaluate the safety and efficacy of ABT-493 and ABT-530, with or without ribavirin (RBV), for 8 to 12 weeks. These data presented at AASLD include non-cirrhotic patients with GT1, GT2 and GT3 chronic HCV infection. Data in additional patient populations (genotypes 4-6) will be presented at future meetings.

"The SURVEYOR trials offer important new information about the potential to treat patients with chronic hepatitis C across multiple genotypes with our two direct-acting antiviral investigational regimen," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "AbbVie's ongoing hepatitis C research program demonstrates our commitment to make a remarkable impact on the lives of HCV patients."

Source: http://www.abbvie.com/


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Patients with non-alcoholic fatty liver disease may benefit from increased dietary niacin intake